HIV Pre-Exposure Prophylaxis (PrEP) Explained

PrEP combines antiretroviral medications taken before potential HIV exposure to prevent acquisition. Daily oral tenofovir/emtricitabine is standard; on-demand protocols exist in some regions for men who have sex with men.

Baseline and periodic HIV testing, kidney function labs, and STI screening accompany prescribing. PrEP does not replace condoms for other STIs.

Cost and insurance coverage vary; patient assistance programs exist. Pharmacists in some locales can initiate or continue PrEP.

If exposure occurs without PrEP, post-exposure prophylaxis (PEP) must begin within 72 hours—often via emergency departments.

How PrEP prevents HIV

Pre-exposure prophylaxis (PrEP) is medication taken by HIV-negative people to prevent infection. Taken as prescribed, it is highly effective at reducing the risk of HIV from sex. It is suited to people at higher risk—those with an HIV-positive partner, multiple partners, or inconsistent condom use—and requires an initial negative HIV test and ongoing monitoring.

Using PrEP effectively

PrEP works only when taken consistently, and it does not protect against other STIs, so condoms and regular screening remain important. Follow-up visits, typically every few months, check HIV status, kidney function, and other STIs. If you have a possible exposure and are not on PrEP, PEP started within 72 hours is the emergency option.

What PrEP Is and How It Works at a Biological Level

Pre-exposure prophylaxis (PrEP) is a medication regimen taken by HIV-negative people to prevent HIV acquisition. The most commonly prescribed formulation is emtricitabine/tenofovir disoproxil fumarate (brand name Truvada), and a newer formulation — emtricitabine/tenofovir alafenamide (Descovy) — is approved for men and transgender women who have sex with men. Injectable cabotegravir (Apretude), administered every two months, is an additional FDA-approved option that removes the need for daily oral medication.

The drugs in PrEP work by blocking the enzyme HIV needs to replicate inside human cells. When taken consistently, they create and maintain drug concentrations in mucosal tissues — genital, rectal, and to a lesser degree oral — high enough to prevent HIV from establishing a productive infection even after exposure. The key word is consistently: protective tissue concentrations build over time (approximately seven days of daily dosing for receptive anal sex protection; around three weeks for vaginal or receptive frontal sex protection). Missing doses reduces concentrations and lowers protection proportionally.

Efficacy: What the Evidence Shows

When taken daily as prescribed, oral PrEP reduces the risk of sexually acquired HIV by approximately 99% in clinical trials. Real-world effectiveness, which accounts for imperfect adherence, is typically reported in the range of 74–92% — still remarkable, and the gap from 99% is attributable almost entirely to missed doses. Among people who take PrEP with high consistency, real-world outcomes closely match clinical trial results.

For people who inject drugs, PrEP reduces HIV acquisition risk by approximately 74% in studies — again, with effectiveness correlating strongly with adherence. Injectable cabotegravir administered on schedule has shown superiority to daily oral tenofovir in clinical trials, making it a particularly valuable option for people who struggle with daily pill adherence. No medication-based HIV prevention method, including PrEP, offers protection against other STIs, which is why STI testing and condom discussions remain part of PrEP care.

Who Should Consider PrEP

PrEP is appropriate for HIV-negative people at substantial ongoing risk of HIV acquisition. This includes men who have sex with men and transgender women who have sex with men — particularly those with multiple partners, those who do not consistently use condoms, or those who use substances that affect sexual decision-making. Heterosexual people whose partner is HIV-positive and not virally suppressed, or who have difficulty negotiating condom use, also have clear indications for PrEP. People who inject drugs and share equipment benefit significantly from PrEP.

Risk is dynamic, not static. Someone who may not need PrEP during a period of lower-risk activity might benefit from initiating it when circumstances change — entering a new relationship, travelling somewhere with higher HIV prevalence, beginning sex work, or experiencing a period of more frequent casual sex. PrEP can be started and stopped based on circumstances, provided the treating clinician is involved in those decisions. There is no obligation to remain on PrEP indefinitely.

Starting PrEP: the Clinical Process

Before initiating PrEP, a clinician must confirm HIV-negative status with a recent test (most guidelines specify testing within the preceding seven days or on the day of initiation). Baseline kidney function is assessed because tenofovir can affect renal tubular cells — most people have no issues, but the check identifies those who need closer monitoring or a different formulation. Hepatitis B status matters because both Truvada and Descovy are active against hepatitis B, and stopping them in someone with hepatitis B can cause hepatitis flares; a clinician needs to account for this in treatment planning.

After starting PrEP, follow-up every three months is standard: HIV testing at each visit to confirm ongoing HIV-negative status, STI screening (important because PrEP users may be at elevated risk for bacterial STIs), kidney function tests every six to twelve months depending on baseline, and a medication refill. These visits are an opportunity to discuss adherence challenges, side effects, and evolving risk factors. Telehealth PrEP services now exist in many regions, reducing travel burden.

Side Effects and Safety Considerations

Most people tolerate daily oral PrEP without significant side effects. A minority experience gastrointestinal symptoms — nausea, loose stools, reduced appetite — in the first few weeks after starting, which typically resolve on their own. Taking the pill with food reduces nausea for most people. Mild headaches are occasionally reported early in the course. Serious side effects are rare; the most clinically relevant is a small reduction in kidney function and bone mineral density with long-term tenofovir disoproxil fumarate use — which is why periodic monitoring is built into standard PrEP care.

Tenofovir alafenamide (Descovy) delivers the active drug more directly into cells, requiring a lower systemic dose and producing fewer kidney and bone effects. It is a suitable alternative for people with pre-existing kidney disease or concerns about long-term bone health, though it is only approved for specific populations as noted above. Injectable cabotegravir has a different side-effect profile, primarily injection-site reactions (pain, swelling, and nodules at the injection site) that are common but generally mild and diminish with subsequent injections.

Cost and Access

Cost has historically been a barrier to PrEP access, but the situation has improved substantially in many countries. In the United States, Truvada's patent expiry has produced generic versions at a fraction of the branded cost. Gilead's patient assistance program (Advancing Access) and the federal Ready, Set, PrEP program provide free medication to eligible uninsured or underinsured people. The ACA requires most private insurance plans to cover PrEP without cost-sharing, including the required clinical visits and tests. Community health centers and sexual health clinics often serve as access points for people without insurance or regular primary care.

Outside the United States, many national health systems include PrEP in their HIV prevention programs at low or no cost. Availability varies significantly by country — some have national PrEP programs with widespread access; others have approved the medication but not funded it publicly. Organizations like the Global Fund and Unitaid support access in lower-income settings. Checking with local HIV advocacy organizations or sexual health services is the most reliable way to find current access options in any location.

Frequently Asked Questions

Does PrEP protect against other STIs besides HIV? No. PrEP is specifically and exclusively effective against HIV. It offers no protection against chlamydia, gonorrhea, syphilis, herpes, HPV, or any other sexually transmitted infection. This is why regular STI screening every three months is part of standard PrEP care, and why condom use alongside PrEP provides broader protection.

Can I stop PrEP and start again later? Yes. PrEP can be taken during periods of higher risk and discontinued during periods of lower risk. If stopping oral PrEP, it should be continued for a short period after the last potential HIV exposure — current guidance suggests 28 days of continued dosing after the last exposure before stopping — to ensure the medication window covers any exposure that occurred near the end of the active period. Always involve a clinician in stopping decisions, particularly if you have hepatitis B co-infection.

What is on-demand PrEP and who is it suitable for? On-demand (or event-driven) PrEP involves taking two pills 2–24 hours before sex, one pill 24 hours after, and one pill 48 hours after sex. This 2-1-1 regimen is supported by clinical trial evidence specifically for cisgender men who have sex with men and has been shown to be highly effective for people who have sex infrequently. It is not currently recommended for transgender women, people with vaginal anatomy, or people who inject drugs, as data are insufficient for these groups. On-demand PrEP provides cost, pill burden, and side-effect advantages for appropriate candidates.